Clinical Trials
22 trialsNCT05145816 2026-05-07
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
University of Texas Southwestern Medical Center
Phase 1/2 Recruiting
NCT07081646 2026-03-24
ALACRITY
Alexion Pharmaceuticals, Inc.
Phase 1/2 Recruiting
NCT06569147 2026-03-06
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Brigham and Women's Hospital
Phase 1/2 Recruiting
NCT06097832 2025-07-10
NEXICART-2
Nexcella Inc.
Phase 1/2 Recruiting
NCT05451771 2025-07-08
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Columbia University
Phase 1/2 Recruiting
NCT05486481 2025-03-06
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
University of California, San Francisco
Phase 1/2 Withdrawn
NCT05199337 2024-09-19
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT03236792 2022-09-29
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT03678259 2022-03-25
124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis
University of Tennessee Graduate School of Medicine
Phase 1/2 Completed
NCT02841033 2021-05-07
Daratumumab for the Treatment of Patients With AL Amyloidosis
Boston Medical Center
Phase 1/2 Completed
NCT00981708 2021-04-30
Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
University of Athens
Phase 1/2 Completed
NCT02545907 2021-04-15
CATALYST
University College, London
Phase 1/2 Completed
NCT01570387 2020-09-22
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
Boston Medical Center
Phase 1/2 Completed
NCT00006251 2020-01-21
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT01707264 2018-08-28
Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Prothena Biosciences Ltd.
Phase 1/2 Completed
NCT00245037 2017-09-27
Bu Flu TBI
OHSU Knight Cancer Institute
Phase 1/2 Completed
NCT00547365 2013-09-19
Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction
University of Tennessee
Phase 1/2 Completed
NCT00003406 2013-03-26
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00823524 2013-02-20
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
Asan Medical Center
Phase 1/2 Completed
NCT01101412 2013-02-15
Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT00621400 2011-05-10
Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis
Nantes University Hospital
Phase 1/2 Completed
NCT00010283 2010-04-02
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
Fred Hutchinson Cancer Center
Phase 1/2 Completed